Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases

被引:15
作者
Chatziioannou, Eftychia [1 ,2 ]
Rossner, Jana [3 ]
Aung, Thazin New [4 ]
Rimm, David L. [4 ]
Niessner, Heike [1 ,2 ]
Keim, Ulrike [1 ]
Serna-Higuita, Lina Maria [5 ]
Bonzheim, Irina [6 ]
Cuellar, Luis Kuhn [7 ]
Westphal, Dana [8 ,9 ,10 ]
Steininger, Julian [8 ,9 ,10 ]
Meier, Friedegund [8 ,9 ,10 ]
Pop, Oltin Tiberiu [11 ]
Forchhammer, Stephan [1 ]
Flatz, Lukas [1 ,11 ]
Eigentler, Thomas [12 ]
Garbe, Claus [1 ]
Roecken, Martin [1 ,2 ]
Amaral, Teresa [1 ,2 ]
Sinnberga, Tobias [1 ,2 ,12 ]
机构
[1] Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany
[2] Cluster Excellence iFIT EXC 2180, Image Guided & Functionally Instructed Tumor Ther, Tubingen, Germany
[3] Heidelberg Univ, Dept Dermatol, Neuenheimer Feld 440, D-69120 Heidelberg, Germany
[4] Yale Univ, Dept Pathol, Sch Med, New Haven, CT USA
[5] Eberhard Karls Univ Tubingen, Dept Clin Epidemiol & Appl Biostat, D-72076 Tubingen, Germany
[6] Eberhard Karls Univ Tubingen, Inst Pathol & Neuropathol, D-72076 Tubingen, Germany
[7] Univ Tubingen, Quant Biol Ctr QBiC, Tubingen, Germany
[8] Tech Univ Dresden, Fac Med, Dept Dermatol, D-01307 Dresden, Germany
[9] Univ Canc Ctr, Univ Hosp Carl Gustav Carus, Skin Canc Ctr, D-01307 Dresden, Germany
[10] Tech Univ Dresden, Natl Ctr Tumor Dis, D-01307 Dresden, Germany
[11] Kantonssp St Gallen, Inst Immunobiol, St Gallen, Switzerland
[12] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Charitepl 1, D-10117 Berlin, Germany
来源
EBIOMEDICINE | 2023年 / 93卷
关键词
Cutaneous melanoma; Prognostic biomarkers; Predictive biomarkers; Tumour-infiltrating lymphocytes; Digital pathology; BREAST-CANCER; SOLID TUMORS; SURVIVAL;
D O I
10.1016/j.ebiom.2023.104644
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Recent advances in digital pathology have enabled accurate and standardised enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a percentage electronic TIL score (eTILs) and investigate its prognostic and predictive relevance in cutaneous melanoma.Methods We included stage I to IV cutaneous melanoma patients and used hematoxylin-eosin-stained slides for TIL analysis. We assessed eTILs as a continuous and categorical variable using the published cut-off of 16.6% and applied Cox regression models to evaluate associations of eTILs with relapse-free, distant metastasis-free, and overall survival. We compared eTILs of the primaries with matched metastasis. Moreover, we assessed the predictive relevance of eTILs in therapy-naive metastases according to the first-line therapy. Findings We analysed 321 primary cutaneous melanomas and 191 metastatic samples. In simple Cox regression, tumour thickness (p < 0.0001), presence of ulceration (p = 0.0001) and eTILs & LE;16.6% (p = 0.0012) were found to be significant unfavourable prognostic factors for RFS. In multiple Cox regression, eTILs & LE;16.6% (p = 0.0161) remained significant and downgraded the current staging. Lower eTILs in the primary tissue was associated with unfavourable relapse-free (p = 0.0014) and distant metastasis-free survival (p = 0.0056). In multiple Cox regression adjusted for tumour thickness and ulceration, eTILs as continuous remained significant (p = 0.019). When comparing TILs in primary tissue and corresponding metastasis of the same patient, eTILs in metastases was lower than in primary melanomas (p < 0.0001). In therapy-naive metastases, an eTILs >12.2% was associated with longer progression-free survival (p = 0.037) and melanoma-specific survival (p = 0.0038) in patients treated with anti-PD-1-based immunotherapy. In multiple Cox regression, lactate dehydrogenase (p < 0.0001) and eTILs & LE;12.2% (p = 0.0130) were significantly associated with unfavourable melanoma-specific survival.Interpretation Assessment of TILs is prognostic in primary melanoma samples, and the eTILs complements staging. In therapy-naive metastases, eTILs & LE;12.2% is predictive of unfavourable survival outcomes in patients receiving anti-PD-1-based therapy.
引用
收藏
页数:19
相关论文
共 71 条
  • [61] Changes in skin cancer screening rates in the United States from 2005 to 2015
    Smith, Brandon
    Smith, Jared E.
    Demanelis, Kathryn
    Ferris, Laura K.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (01) : 142 - 145
  • [62] Prognostic Significance of Tumor-Infiltrating Lymphocyte Grade in Melanoma: A Meta-Analysis
    Sun, Qian
    Sun, Hongyan
    Wu, Nan
    Cong, Lele
    Cong, Xianling
    [J]. DERMATOLOGY, 2020, 236 (06) : 481 - 492
  • [63] Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature
    Svedman, Fernanda Costa
    Pillas, Demetris
    Taylor, Aliki
    Kaur, Moninder
    Linder, Ragnar
    Hansson, Johan
    [J]. CLINICAL EPIDEMIOLOGY, 2016, 8 : 109 - 122
  • [64] Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
    Teterycz, Pawel
    Lugowska, Iwona
    Kosela-Paterczyk, Hanna
    Rutkowski, Piotr
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (1)
  • [65] Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
    Tirosh, Itay
    Izar, Benjamin
    Prakadan, Sanjay M.
    Wadsworth, Marc H., II
    Treacy, Daniel
    Trombetta, John J.
    Rotem, Asaf
    Rodman, Christopher
    Lian, Christine
    Murphy, George
    Fallahi-Sichani, Mohammad
    Dutton-Regester, Ken
    Lin, Jia-Ren
    Cohen, Ofir
    Shah, Parin
    Lu, Diana
    Genshaft, Alex S.
    Hughes, Travis K.
    Ziegler, Carly G. K.
    Kazer, Samuel W.
    Gaillard, Aleth
    Kolb, Kellie E.
    Villani, Alexandra-Chloe
    Johannessen, Cory M.
    Andreev, Aleksandr Y.
    Van Allen, Eliezer M.
    Bertagnolli, Monica
    Sorger, Peter K.
    Sullivan, Ryan J.
    Flaherty, Keith T.
    Frederick, Dennie T.
    Jane-Valbuena, Judit
    Yoon, Charles H.
    Rozenblatt-Rosen, Orit
    Shalek, Alex K.
    Regev, Aviv
    Garraway, Levi A.
    [J]. SCIENCE, 2016, 352 (6282) : 189 - 196
  • [66] Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
    Tucci, Marco
    Passarelli, Anna
    Mannavola, Francesco
    Felici, Claudia
    Stucci, Luigia Stefania
    Cives, Mauro
    Silvestris, Francesco
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [67] PD-1 blockade induces responses by inhibiting adaptive immune resistance
    Tumeh, Paul C.
    Harview, Christina L.
    Yearley, Jennifer H.
    Shintaku, I. Peter
    Taylor, Emma J. M.
    Robert, Lidia
    Chmielowski, Bartosz
    Spasic, Marko
    Henry, Gina
    Ciobanu, Voicu
    West, Alisha N.
    Carmona, Manuel
    Kivork, Christine
    Seja, Elizabeth
    Cherry, Grace
    Gutierrez, Antonio J.
    Grogan, Tristan R.
    Mateus, Christine
    Tomasic, Gorana
    Glaspy, John A.
    Emerson, Ryan O.
    Robins, Harlan
    Pierce, Robert H.
    Elashoff, David A.
    Robert, Caroline
    Ribas, Antoni
    [J]. NATURE, 2014, 515 (7528) : 568 - +
  • [68] The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival
    Valpione, Sara
    Mundra, Piyushkumar A.
    Galvani, Elena
    Campana, Luca G.
    Lorigan, Paul
    De Rosa, Francesco
    Gupta, Avinash
    Weightman, John
    Mills, Sarah
    Dhomen, Nathalie
    Marais, Richard
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [69] Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor
    von Schuckmann, Lena A.
    Hughes, Maria Celia B.
    Ghiasvand, Reza
    Malt, Maryrose
    van der Pols, Jolieke C.
    Beesley, Vanessa L.
    Khosrotehrani, Kiarash
    Smithers, B. Mark
    Green, Adele C.
    [J]. JAMA DERMATOLOGY, 2019, 155 (06) : 688 - 693
  • [70] Role of tumor microenvironment in tumorigenesis
    Wang, Maonan
    Zhao, Jingzhou
    Zhang, Lishen
    Wei, Fang
    Lian, Yu
    Wu, Yingfeng
    Gong, Zhaojian
    Zhang, Shanshan
    Zhou, Jianda
    Cao, Ke
    Li, Xiayu
    Xiong, Wei
    Li, Guiyuan
    Zeng, Zhaoyang
    Guo, Can
    [J]. JOURNAL OF CANCER, 2017, 8 (05): : 761 - 773